Trial Profile
Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs BGC-101-BioGenCell (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms EnEPC-CLI
- Sponsors BioGenCell
- 07 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 07 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 07 Nov 2022 Status changed from active, no longer recruiting to recruiting.